Funding – June 3, 2026
Thålin has been awarded the Swedish Heart-Lung Foundation’s major research grant for her work on antibody-based protection against infections in chronic obstructive pulmonary disease (COPD).
Science article – June 3, 2026
Growing two or three-dimensional human nasal tissue can lead to better reliability in research studies, personalized treatment strategies, and ultimately contribute to better outcomes for patients.
Pharma Business – June 3, 2026
Herantis Pharma provides an update on preparations for the Phase 2a proof-of-concept efficacy study of HER-096, its lead candidate for the treatment of Parkinson’s disease.
Financing – June 3, 2026
Stayble Therapeutics has announced that its Board of Directors has resolved to file for bankruptcy, with the application to be submitted to the Gothenburg District Court.
Acquisition – June 2, 2026
French pharma company Servier has entered into an agreement to acquire the muscular dystrophy business of US Edgewise Therapeutics for up to USD 2.65 billion, including upfront payment of USD 1.55 billion as well as up to USD1.1 billion in regulatory and commercial milestone payments.
Collaboration – June 2, 2026
The company has announced a new collaboration with the research group of Dr. Thuy Tran at the Department of Oncology-Pathology, Karolinska Institutet.
Clinical Trials – May 25, 2026
Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.
Clinical Trials – May 20, 2026
Oncopeptides’ clinical trial application for the “Window-of-Opportunity” (WoO) study in glioblastoma has been formally approved in Norway.
Clinical Trials – May 19, 2026
Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.
Clinical Trials – May 12, 2026
AnaCardio has announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).
Clinical Trials – May 6, 2026
The independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq/kg to provide a basis for defining a recommended phase II dose and completion of the phase I part of the study.
Clinical Trials – April 24, 2026
Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).
Thea Nordic
PharmaRelations is now looking for a Head of Clinical Operations who wants to continue to build up and develop our business in Denmark and South of Sweden (Öresundsregionen).
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations who wants to continue to build up and develop our business in Denmark and South of Sweden (Öresundsregionen).
Cellcolabs AB
We are partnering with Cellcolabs to identify a Chief Medical Officer, who will play a central role in shaping the company’s continued clinical, scientific, and international growth.
Confidential
The position combines strategic account management, in‑field execution and cross‑functional collaboration with Medical Affairs and Market Access.
Daiichi Sankyo Nordics
Now, we’re looking for a senior HEOR Manager with a solid HTA toolbox who can help secure and expand access to groundbreaking oncology treatments for patients in the Nordics. You will join Daiichi Sankyo, driven by more than 120 years of innovation and a deep global commitment to improving lives.
PharmaRelations
PharmaRelations is the Nordic Market Leader within Talent services for the Life Science industry. We specialize in partnering with some of the top and most innovative organizations exclusively in the Life Science sector across our region.
In a new job – May 14, 2026
Finnish Bioindustries Association has elected a new Board of Directors:
In a new job – May 13, 2026
Jane Hvolbæk Nielsen brings, besides an internationally recognized career in materials science research, 15 years of experience in leading and managing a large scientific organisation.
In a new job – May 4, 2026
James Lee brings more than 25 years of experience in the international pharmaceutical and healthcare sector, with a track record of launching innovative medicines and scaling global healthcare brands, according to the company.
Careers article – May 5, 2026
BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts, it states. The company plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up […]
Career choice – April 14, 2026
Anna Carbery’s research looks at how we can implement AI-driven peptide design to make new cancer therapeutics.
Careers article – March 31, 2026
As Sweden crowns its national champions in youth research, the country is grappling with a deeper challenge: how to inspire more young people to pursue science, technology, and maths at a time when PISA results reveal a steady decline in STEM competence across the Nordics.
Profiles in Science – April 22, 2026
It’s one thing to “do” physics – but it’s another to explain its fundamentals to others, and the role that physics and other sciences play in their lives.
Profiles in Science – March 23, 2026
Dr. Joanna Rorbach, principal researcher at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, has been awarded the prestigious Göran Gustafsson Prize by the Royal Swedish Academy of Sciences (Kungliga Vetenskapsakademien).
Profiles in Business – December 8, 2025
Successful businessman and former chairman of AstraZeneca, Leif Johansson, has accumulated vast experience and knowledge about international competition, leadership, business development, and entrepreneurship, not least when it comes to science-driven industries like the life science industry.
Pharma Business – May 29, 2026
The Uppsala site has been established to support scientific collaboration, application development and resin innovation.
Agreement – May 26, 2026
The two companies have partnered to offer an integrated development and manufacturing pathway for recombinant protein programs in E. coli.
Agreement – May 26, 2026
The agreement for distribution and commercialization of Pepaxti in Central and Eastern Europe addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states.
Agreement – June 2, 2026
The agreement enables access to Ankyras clinical decision-support software with the Siemens Healthineers ARTIS icono angiography systems and includes joint promotional activities through the ARTIS icono product platform.
Digital health – May 27, 2026
Skape Bio and researchers at the University of Washington’s Institute for Protein Design (IPD) have announced a peer-reviewed study published in Nature demonstrating a new way to design protein-based medicines for G protein-coupled receptors, or GPCRs.
Collaboration – May 11, 2026
Bactiguard Holding has announced an update to its long standing collaboration with license partner BD (Becton, Dickinson & Company) through the signing of a restated long-term agreement.
Agreement – May 19, 2026
Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.
Biotech Business – May 11, 2026
BioArctic’s partner Eisai has announced that the FDA has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi Iqlik, as a starting dose for the treatment of early Alzheimer’s disease.
Biotech Business – May 11, 2026
Oncopeptides has announced its intention to submit a Type II variation application to the European Medicines Agency (EMA).
Science Award – May 8, 2026
Professor Charlotte Ling of Lund University in Sweden has fundamentally changed the scientific understanding of type 2 diabetes by showing that the disease arises through an interplay between genes and environmental influences that alter which genes are active.
Funding – April 29, 2026
Through a donation, a new foundation has been formed called Familjen Landegrens stiftelse för medicinsk forskning (Landegren Family Foundation for Medical Research). The purpose of this foundation is to support Uppsala University’s medical research and medical innovation.
Science article – April 26, 2026
For a long time, restoring vision has been like a search for the holy grail for scientists. And for many patients, being diagnosed with a severe retinal disease has meant progressive, irreversible vision loss. However, the past decade has seen some of the clearest evidence so far that vision loss can be partially restored, not just preserved.
This site uses cookies
